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1. INTRODUCTION {#cam41533-sec-0001}
===============

Anal squamous cell carcinoma (ASCC) is a rare tumor, but its incidence has been increasing over the past 2 decades.[1](#cam41533-bib-0001){ref-type="ref"}, [2](#cam41533-bib-0002){ref-type="ref"}, [3](#cam41533-bib-0003){ref-type="ref"} This cancer is closely related to human papillomavirus (HPV) infection.[4](#cam41533-bib-0004){ref-type="ref"} Most patients are diagnosed with locally advanced disease, for which the standard of care is chemoradiotherapy (CRT).[5](#cam41533-bib-0005){ref-type="ref"} High complete response rates are obtained, but 20% of patients are nonresponders or relapse within the first 3 years after treatment. Salvage abdominoperineal resection (APR) is the standard treatment for local failure or recurrence after CRT, but 30% to 60% of operated patients subsequently experience locoregional and/or metastatic recurrence.[6](#cam41533-bib-0006){ref-type="ref"}, [7](#cam41533-bib-0007){ref-type="ref"} Very few treatments with very limited efficacy are available for these patients with inoperable locally advanced or metastatic disease. A better understanding of the molecular markers involved in anal carcinogenesis is necessary in order to identify new therapeutic targets as well as prognostic and predictive biomarkers. In comparison with other squamous cell carcinomas and HPV‐related cancers, the molecular landscape of ASCC is currently not well characterized and few genomic studies are available.[8](#cam41533-bib-0008){ref-type="ref"}, [9](#cam41533-bib-0009){ref-type="ref"}, [10](#cam41533-bib-0010){ref-type="ref"} Only limited and old data are available concerning the recurrent pattern of chromosomal aberrations in ASCC.[11](#cam41533-bib-0011){ref-type="ref"}, [12](#cam41533-bib-0012){ref-type="ref"} Only one study was based on a comparative genomic hybridization (CGH) approach, but concerned a cohort of 35 cases of anal intra‐epithelial neoplasia.[13](#cam41533-bib-0013){ref-type="ref"} In this study, we present the results of array‐CGH analysis of 49 ASCC patients with comparison of genomic profiles between treatment‐naive tumors and recurrences.

2. MATERIALS AND METHODS {#cam41533-sec-0002}
========================

2.1. Sample collection {#cam41533-sec-0003}
----------------------

Forty‐nine tumor samples from 49 patients with ASCC (ie, no paired samples from same patients) treated between 1992 and 2015 at the Institut Curie Hospital were retrospectively analyzed. All biopsy tissues were residual specimens and macrodissected to achieve maximum tumor purity. A fresh frozen tumor sample was considered suitable for the study when the proportion of tumor cells exceeded 70%. This retrospective study was reviewed and approved by the Institut Curie Ethics Committee (No. A10‐024). According to French regulations, patients were informed about the research performed on the biological specimens obtained during their treatment and did not express any opposition. Clinical and laboratory data were collected for each patient. Disease staging was based on the 7th revised edition (2010) of the American Joint Committee on Cancer (AJCC) staging of anus cancer. Fifteen samples of adjacent normal anal squamous cell tissue from patients with ASCC were used as sources of normal RNA for RT‐qPCR. Tissues samples were stored at −70°C until DNA and RNA extractions.

2.2. Genomic DNA extraction {#cam41533-sec-0004}
---------------------------

The Qiagen DNeasy Tissue kit and the protocols for fresh frozen ASCC tissues were used. DNA was purified by column purification with a filter membrane and stored at −20°C before use.

2.3. Total RNA extraction {#cam41533-sec-0005}
-------------------------

Total RNA was extracted from fresh frozen ASCC and normal anal squamous cell tissues by the acid‐phenol guanidium method. The quantity of RNA was assessed using an ND‐1000 NanoDrop Spectrophotometer with its corresponding software (Thermo Fisher Scientific Inc., Wilmington, DE). RNA quality was determined by electrophoresis on agarose gel with ethidium bromide staining. The 18S and 28S RNA bands were visualized under ultraviolet light. Total RNA was stored at −20°C before use.

2.4. HPV genotyping {#cam41533-sec-0006}
-------------------

HPV status was assessed in the Institut Curie Pathology Department. Total DNA, isolated from formalin‐fixed tissue blocks, was used for HPV typing. Real‐time PCR using Sybr^®^Green and specific primers for HPV16 and 18 was performed on a 7900HT Fast Real‐Time PCR System (Applied Biosystems, Foster City, CA).

2.5. Mutation assessment {#cam41533-sec-0007}
------------------------

HRM primers for screening mutations were designed for *KRAS* (exons 2, 3, and 4), *BRAF* (exon 15), *PIK3CA* (exons 9 and 20), and *TP53* (exons 5‐8). PCR for HRM analysis was performed on a 384‐well plate in the presence of the fluorescent DNA intercalating dye, LC green (Idaho Technology) in a LightCycler480^®^ (Roche). HRM analysis was performed with Genescan software (Roche). All samples were plotted according to their melting profiles on the differential plot graph. All samples were sequenced using Sanger sequencing approach, whenever an abnormal HRM curve was suspected. The nucleotide sequences of the oligonucleotide primers for the genes examined are listed in Table [S1](#cam41533-sup-0004){ref-type="supplementary-material"}.

2.6. Array‐CGH {#cam41533-sec-0008}
--------------

ASCCs were tested using a 400K human genome CGH microarray. Array‐CGH experiments were carried out using standard Agilent protocols (Agilent Technologies, Santa Clara, CA). Commercial human genomic DNA (Agilent Technologies) was used as diploid reference. Briefly, 1‐1.5 μg of reference DNA and the same amounts of patient tumor DNA were digested with Alu1 and Rsa1 (Promega, Madison, WI, USA). The digested reference DNA fragments were labeled with cyanine 3‐dUTP, and tumor DNA was labeled with cyanine 5‐dUTP (Agilent Technologies). After cleanup, labeled reference and tumor DNA were mixed as probes and hybridized onto an Agilent 400K human genome CGH microarray (Agilent Technologies) for 40 hours. Washing, scanning, and data extraction procedures were carried out according to standard protocols. Data were extracted using Feature Extraction software (v11.1), and normalized data were analyzed and visualized by Agilent Cytogenomics Edition 2.9.2.4 (Agilent Technologies). The aberration detection module 2 (ADM‐2) with threshold 6 was used to calculate copy number alterations (CNAs). Five‐probe 0.20_log2 filter was used for aberration evaluation, given an average genomic resolution of 7 Kb. DGV database (hg19) was used for elimination of the common copy number polymorphism regions from the dataset. Cytogenomics Edition 2.9.2.4 (Agilent Technologies) was used to calculate the log2 ratio for each probe and to identify genomic aberrations. The mean log2 ratio of all probes in a chromosome region between 0.20 and 1.0 was classified as genomic gain, more than 1.0 (with a size \<10 Mb) as focal amplification, less than −0.30 as heterozygous deletion, and less than −1.0 (with a size \<5 Mb) as homozygous deletion.

2.7. RT‐qPCR {#cam41533-sec-0009}
------------

The theoretical and practical aspects of RT‐qPCR have been previously described in detail.[14](#cam41533-bib-0014){ref-type="ref"} The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (ie, lack of extensive degradation) are both difficult to assess. Transcripts of an endogenous RNA control gene involved in cellular metabolic pathway, namely *TBP* (Genbank accession [NM_003194](NM_003194)),[15](#cam41533-bib-0015){ref-type="ref"} which encodes the TATA box‐binding protein (a component of the DNA‐binding protein complex TFIID), were therefore also quantified. Each sample was normalized on the basis of its *TBP* content. Results, expressed as N‐fold differences in target gene expression relative to the *TBP* gene and termed "N*target*," were determined as N*target* = 2^ΔCtsample^, where the Δ*Ct* value of the sample was determined by subtracting the *Ct* value of the target gene from the *Ct* value of the *TBP* gene. The N*target* values of the samples were subsequently normalized so that the median of the 15 normal anal squamous cell tissue N*target* values was 1. cDNA synthesis and PCR conditions were as previously described.[14](#cam41533-bib-0014){ref-type="ref"} Primers for *TBP* and the target genes were designed with the assistance of Oligo 6.0 software (National Biosciences, Plymouth, MN). To avoid amplification of contaminating genomic DNA, 1 of the 2 primers was placed at the junction between 2 exons or on between 2 different exons. Agarose gel electrophoresis was used to verify the specificity of PCR amplicons. The nucleotide sequences of the oligonucleotide primers for the selected genes are listed in Table [S2](#cam41533-sup-0005){ref-type="supplementary-material"}.

2.8. Statistical analysis {#cam41533-sec-0010}
-------------------------

Correlations between molecular parameters (at the RNA or/and DNA level), and clinical, biological, and pathological parameters, were identified using nonparametric tests, namely Chi‐square or Fisher's exact test (correlation between 2 qualitative parameters), and Kruskal‐Wallis test (correlation between 1 qualitative parameter and 1 quantitative parameter). OS was defined as the interval from the first day of RT or CRT to death from any cause. In order to assess the efficacy of a molecular marker (number of altered regions and fraction of genome altered) to discriminate between 2 populations (alive/deceased patients) in the absence of an arbitrary cutoff value, data were summarized in a ROC (receiver operating characteristic) curve.[16](#cam41533-bib-0016){ref-type="ref"} The area under curve (AUC) was calculated as a single measure to discriminate efficacy. Survival distributions were estimated by the Kaplan‐Meier method, and the significance of differences between survival rates was ascertained with the log‐rank test. For all statistical tests, differences were considered significant at *P *\<* *.05.

3. RESULTS {#cam41533-sec-0011}
==========

3.1. Patient and tumor characteristics {#cam41533-sec-0012}
--------------------------------------

A total of 49 ASCC samples from 49 patients treated in our institution were included and analyzed for CNA and *KRAS, BRAF, PIK3CA,* and *TP53* mutations. Tumor characteristics in the total population according to the treatment‐naive or recurrence status of the samples are summarized in Table [S3](#cam41533-sup-0006){ref-type="supplementary-material"}. Twenty‐seven tumors were treatment‐naive and 22 were samples from recurrence after initial RT or CRT. A total of 46 tumors (93.9%) were HPV‐positive, including 43 tumors (87.5%) with HPV16 infection. Only 4 patients (8.2%) had HIV infection, and all presented concomitant HPV infection. The study population comprised 38 females and 11 males. Eight patients were treated by first‐line surgery: exclusive surgery (n = 4) and surgery followed by RT (n = 3) or CRT (n = 1). Twelve patients were treated by first‐line RT and 29 by first‐line CRT. The median follow‐up of the 49 patients was 46.2 months (range: 9.8 to 278 months). Eight of the 27 treatment‐naive patients relapsed after the initial diagnosis.

3.2. Whole‐genome array‐CGH profiles {#cam41533-sec-0013}
------------------------------------

Array‐CGH profiles of the 49 ASCCs are represented in Figure [1](#cam41533-fig-0001){ref-type="fig"}A. Gains and deletion metrics for each sample are listed in Table [S4](#cam41533-sup-0007){ref-type="supplementary-material"}. The first genomic parameter corresponds to the number of distinct identified CGH segments reflecting the number of break points within the tumor genome. This parameter ranged from 68 to 550, with a median of 137. The second genomic parameter corresponds to the fraction (percentage) of the altered genome. This parameter ranged from 0.96% to 51.94%, with a median of 17.82%.

![Frequency of chromosomal alterations using array‐CGH in ASCC tumors (*x‐*axis:chromosomes; *y*‐axis:frequency (in percentages) of copy number gains (blue) and losses (red) in the total population of 49 ASCCs (A), in the group of 27 treatment‐naive tumors (B) and in the group of 22 recurrences (C))](CAM4-7-3213-g001){#cam41533-fig-0001}

3.3. Heterozygous and homozygous deletions {#cam41533-sec-0014}
------------------------------------------

The most significantly frequent minimal regions of heterozygous deletion with a frequency greater than 25% were located at loci 2q35 (27%), 2q36.3 (29%), 3p21.2 (39%), 4p16.3 (29%), 4p31.21 (27%), 7q36.1 (27%), 8p23.3 (41%), 10q23.2 (27%), 11q22.3 (55%), and 13q14.11 (22%) (Table [1](#cam41533-tbl-0001){ref-type="table"}A; Figure [1](#cam41533-fig-0001){ref-type="fig"}A). The most common frequent minimal region of heterozygous deletion in 55% of ASCCs encompassed the 8.4‐Mb region containing *ATM* (Figure [S1](#cam41533-sup-0001){ref-type="supplementary-material"}). Other common regions of heterozygous genomic deletion containing well‐known tumor suppressor genes were located at 3p21.2 (*BAP1, PBRM1,* and *FHIT*), 10q23.2 (*PTEN*, that also showed 2 homozygous deletions; Figure [S2](#cam41533-sup-0002){ref-type="supplementary-material"}), and 13q14.11 (*RB1*) (Table [1](#cam41533-tbl-0001){ref-type="table"}A). Expression of *ATM* and *PTEN* located in 2 of the smallest common CNAs of interest was then screened for 41 of the 49 ASCC using RT‐qPCR to assess correlations between copy number alterations and mRNA expressions in ASCC tumors. *ATM* and *PTEN* were significantly underexpressed in ASCCs with heterozygous/homozygous deletions, compared to diploid tumors (*P *=* *.006 and *P *=* *.02, respectively; Figures [S1](#cam41533-sup-0001){ref-type="supplementary-material"} and [S2](#cam41533-sup-0002){ref-type="supplementary-material"}).

###### 

Frequencies (greater than 20%) of loss/deletion (A) and gain/amplification (B) for each chromosomal arm

  \(A\) Loss and deletion                                                                                                                                                                              
  ----------------------------------------------------------------------------------------- ---------- ------- --------------------- ---------- ----- -------------------------------- ------- ------- -----------
  2q                                                                                        2q35       26.53   220197899‐225875177   5677578    30    *PAX3, CUL3*                     18.52   36.36   .16 (NS)
  2q                                                                                        2q36.3     28.57   230579286‐233243243   2663957    37    *TRIP12*                         29.63   31.82   .87 (NS)
  3p                                                                                        3p21.2     38.78   50712594‐74311719     23599125   167   *BAP1, PBRM1, FHIT*              40.74   54.55   .34 (NS)
  4p                                                                                        4p16.3     28.57   1400230‐44018877      42618647   247   *WHSC1*                          29.63   22.73   .59 (NS)
  4q                                                                                        4q31.21    26.53   145659881‐162305043   16645162   78    *FBXW7*                          29.63   18.18   .35 (NS)
  7q                                                                                        7q36.1     26.53   151217010‐152133979   916969     5     *KMT2C*                          22.22   31.82   .45 (NS)
  8p                                                                                        8p23.3     40.81   419875‐29952921       29533046   266   *NKX3‐1, NEFL, DUSP4*            25.93   18.18   .76 (NS)
  10q                                                                                       10q23.2    26.53   89625664‐89722948     97284      1     *PTEN*                           33.33   18.18   .23 (NS)
  11q                                                                                       11q22.3    55.10   107197072‐115631345   8434273    78    *ATM*                            62.96   45.45   .22 (NS)
  13q                                                                                       13q14.11   22.45   41837713‐50623108     8785395    85    *RB1*                            22.22   22.73   .76 (NS)
  Significant (or trending toward) differences between treatment‐naive and recurrent ASCC                                                                                                              
  11q                                                                                       11q14.2    30.61   85631063‐89867817     4236754    28    *EED*                            48.14   9.09    .0032
  16q                                                                                       16q11.2    20.41   34990995‐90142338     55151343   475   *CYLD, CBFB, CTCF, CDH1, WWOX*   29.63   4.55    .059 (NS)

  \(B\) Gain and amplification                                                                                                                                         
  -------------------------------------------------------------------- ---------- ------- --------------------- ---------- ----- --------------------- ------- ------- -----------
  1p                                                                   1p36.33    36.73   855072‐1447522        592450     42    *TNFRSF18, TNFRSF4*   33.33   40.91   .58 (NS)
  1q                                                                   1q21.1     28.57   148951595‐149871154   919559     18    ---                   29.63   27.27   .86 (NS)
  3q                                                                   3q26.32    57.14   160788817‐197807542   37018725   284   *TERC, PIK3CA*        59.26   54.55   .75 (NS)
  5p                                                                   5p15.33    28.57   190087‐535954         345867     11    *AHRR*                22.22   36.36   .28 (NS)
  8q                                                                   8q24.3     38.78   144442147‐145754562   1312415    71    ---                   40.74   36.36   .75 (NS)
  9q                                                                   9q34.3     32.65   138853226‐140201345   1348119    79    *NOTCH1*              33.33   31.82   .91 (NS)
  16p                                                                  16p13.3    40.82   333003‐903634         570631     37    ---                   40.74   18.18   .088 (NS)
  19p                                                                  19p13.3    26.53   474983‐685520         210537     10    *FGFR2*               33.33   18.18   .23 (NS)
  Significant differences between treatment‐naive and recurrent ASCC                                                                                                   
  1p                                                                   1p32.3     20.41   55681039‐68297970     12616931   75    *JUN*                 29.63   9.09    .16 (NS)
  19                                                                   19q13.42   20.41   55995854‐56111705     115851     6     ---                   33.33   4.55    .033

John Wiley & Sons, Ltd

Fifty‐four homozygous deletions were identified, including 5 recurrent homozygous deletions for the loci: *LRP1B* (2q21.2; n = 2), *TGFBR2* (3p22; n = 4), *PTEN* (10q23.3; n = 2), *TRAF3* (14q32.32; n = 2), and *MACROD2* (20p12.1; n = 3) (Table [2](#cam41533-tbl-0002){ref-type="table"}A). The smallest common deleted region of 4 homozygous deleted tumors at 3p22 affected nucleotides 30, 601, 218‐30, 715, and 674 (deletion size of 114 456 bp) and encompassed the promoter and the first 5 exons of *TGFBR2* gene (Figure [2](#cam41533-fig-0002){ref-type="fig"}).

###### 

Homozygous deletions (A) and focal amplifications (B) in the series of 49 ASCCs

  Tumor number                 Chromosome   Genomic position[a](#cam41533-note-0004){ref-type="fn"}   Size (Kb)   Candidate cancer genes   Number of additional genes                          
  ---------------------------- ------------ --------------------------------------------------------- ----------- ------------------------ --------------------------------------------------- -----
  \(A\) Homozygous deletions                                                                                                                                                                   
  T42                          2q           141719777                                                 142287302   568                      **LRP1B** [b](#cam41533-note-0005){ref-type="fn"}   0
  T41                          2q           141961813                                                 142097960   136                      **LRP1B**                                           0
  T49                          2q           222721345                                                 222774000   53                       ---                                                 0
  T35                          3p           30152477                                                  30833735    681                      **TGFBR2**                                          1
  T13                          3p           30251811                                                  30729096    478                      **TGFBR2**                                          0
  T30                          3p           30601218                                                  32529689    1928                     **TGFBR2**                                          8
  T34                          3p           30601218                                                  30715674    114                      **TGFBR2**                                          0
  T7                           3p           56942992                                                  57108140    165                      ---                                                 2
  T33                          3p           57389175                                                  57614051    225                      ---                                                 4
  T36                          3p           60431642                                                  60504289    73                       FHIT                                                0
  T22                          3q           107001161                                                 107379667   379                      ---                                                 3
  T45                          4q           87390704                                                  87643400    253                      PTPN13                                              0
  T45                          4q           150441915                                                 150902655   461                      ---                                                 0
  T23                          4q           151347901                                                 151564275   216                      ---                                                 2
  T45                          4q           153420602                                                 153552364   132                      FBXW7                                               2
  T44                          5q           58940595                                                  59446730    506                      ---                                                 1
  T37                          6p           29854870                                                  29903186    48                       ---                                                 3
  T8                           7q           134132030                                                 134154953   23                       ---                                                 1
  T23                          7q           151856130                                                 151900145   44                       MLL3                                                0
  T14                          8p           16040684                                                  16624068    583                      MSR1                                                0
  T37                          8q           107695457                                                 107813781   118                      ---                                                 2
  T43                          9p           6575628                                                   6690027     114                      ---                                                 1
  T44                          9p           8807702                                                   10060074    1252                     ---                                                 1
  T44                          9p           21583983                                                  22125464    541                      CDKN2A                                              4
  T43                          9q           115769754                                                 115812331   43                       ---                                                 2
  T30                          10p          647277                                                    912575      265                      ---                                                 3
  T30                          10p          4862123                                                   5888319     1026                     ---                                                 15
  T31                          10q          89348185                                                  91128004    1780                     **PTEN**                                            19
  T30                          10q          89625664                                                  89722948    97                       **PTEN**                                            0
  T31                          10q          101206545                                                 101458546   252                      ---                                                 3
  T9                           10q          103741298                                                 103871109   130                      ---                                                 3
  T9                           10q          124348251                                                 124351778   4                        ---                                                 1
  T41                          11p          10040789                                                  10160579    120                      ---                                                 1
  T14                          11p          19164556                                                  19177503    13                       ---                                                 1
  T2                           11q          85418464                                                  85975246    557                      EED                                                 3
  T7                           13q          48685540                                                  49189327    504                      RB1                                                 3
  T45                          13q          50747777                                                  50876900    129                      ---                                                 2
  T45                          13q          60342599                                                  60715215    373                      ---                                                 1
  T45                          13q          100793061                                                 101042369   249                      ---                                                 1
  T31                          14q          28339878                                                  30047566    1708                     ---                                                 3
  T7                           14q          103226005                                                 103336569   111                      **TRAF3**                                           0
  T31                          14q          103315491                                                 103531760   216                      **TRAF3**                                           2
  T8                           15q          60639903                                                  60728450    89                       ---                                                 0
  T36                          16p          6274664                                                   6943369     669                      ---                                                 1
  T43                          16p          21599687                                                  21739911    140                      ---                                                 3
  T31                          16p          32077887                                                  33773163    1695                     ---                                                 6
  T4                           16q          83115013                                                  83432724    318                      ---                                                 1
  T31                          17p          20839079                                                  20931919    93                       ---                                                 1
  T45                          20p          14786361                                                  14824431    38                       **MACROD2**                                         0
  T17                          20p          14808927                                                  14916449    108                      **MACROD2**                                         1
  T41                          20p          14685390                                                  14884788    199                      **MACROD2**                                         1
  T46                          Xp           50653790                                                  50674794    21                       ---                                                 1
  T33                          Xq           137430350                                                 137745714   315                      ---                                                 2
  T49                          Xp           7073279                                                   7152984     80                       ---                                                 1
  \(B\) Focal amplifications                                                                                                                                                                   
  T45                          1p           94117825                                                  99305935    5188                     ---                                                 23
  T11                          1q           146633992                                                 149243967   2609                     ---                                                 4
  T42                          1q           150468933                                                 150552007   83                       MCL1                                                4
  T45                          1q           156955933                                                 163053407   6097                     **DDR2**                                            121
  T11                          1q           159912739                                                 169695388   9783                     **DDR2**                                            119
  T23                          1q           160549202                                                 165142132   4592                     **DDR2**                                            57
  T45                          1q           239756962                                                 249197762   9441                     ---                                                 94
  T11                          2q           98263510                                                  102700794   4437                     ---                                                 25
  T11                          2q           191215415                                                 191612261   397                      ---                                                 4
  T45                          3p           159711                                                    7170996     7011                     ---                                                 21
  T45                          3p           13466423                                                  19384217    5918                     ---                                                 39
  T11                          3p           82429355                                                  83938826    1509                     ---                                                 1
  T27                          3q           100342240                                                 100438926   97                       ---                                                 2
  T11                          4p           17129095                                                  22302368    5173                     ---                                                 14
  T3                           4q           58881742                                                  59279688    398                      ---                                                 0
  T11                          5p           70922229                                                  73562716    2640                     ---                                                 15
  T45                          5q           50399526                                                  51613550    1214                     ---                                                 1
  T45                          6p           5999325                                                   7631832     1632                     ---                                                 11
  T45                          6p           8581055                                                   9797451     1216                     ---                                                 4
  T45                          6p           52423397                                                  52957234    534                      ---                                                 11
  T45                          7q           89982243                                                  92947957    2966                     CDK6                                                20
  T45                          7q           111497007                                                 113531594   2035                     ---                                                 9
  T45                          7q           116428644                                                 117701988   1273                     MET                                                 10
  T18                          8p           8887305                                                   11998652    3111                     ---                                                 34
  T18                          8p           16829810                                                  20745858    3916                     ---                                                 30
  T45                          8p           28165470                                                  29132608    967                      ---                                                 9
  T1                           8p           31705338                                                  32599619    894                      NRG1                                                0
  T4                           8p           40516566                                                  41801388    1285                     **SFRP1, NKX6‐3**                                   7
  T17                          8p           40976967                                                  42023028    1046                     **SFRP1, NKX6‐3**                                   7
  T15                          8q           51172683                                                  51897027    724                      ---                                                 1
  T45                          8q           127958754                                                 128737245   778                      **MYC**                                             2
  T12                          8q           128648487                                                 128931662   283                      **MYC**                                             1
  T48                          11p          2020361                                                   2156216     0.1                      IGF2                                                0
  T42                          11q          68468717                                                  70627125    2158                     **CCND1**                                           18
  T18                          11q          68777026                                                  70256004    1479                     **CCND1**                                           13
  T13                          11q          69299678                                                  71293376    1994                     **CCND1**                                           18
  T11                          12q          65432368                                                  73724943    8293                     MDM2                                                23
  T1                           13q          27690631                                                  31048425    3358                     FLT3                                                19
  T9                           15q          20416244                                                  21933319    1517                     ---                                                 6
  T23                          15q          64404754                                                  64561193    156                      ---                                                 4
  T11                          17q          52817574                                                  53798187    981                      ---                                                 6
  T23                          17q          69107506                                                  71705679    2598                     SOX9                                                10
  T13                          18q          30225878                                                  33090589    2618                     **MAPRE2**                                          8
  T48                          18q          31621014                                                  32675976    1055                     **MAPRE2**                                          3
  T14                          18q          58632332                                                  61297905    2666                     BCL2                                                12
  T11                          19p          1149294                                                   1298701     149                      ---                                                 9
  T17                          19p          13080354                                                  13211568    131                      **NFIX,LYL1**                                       1
  T12                          19p          13136304                                                  13218303    82                       **NFIX,LYL1**                                       1
  T45                          19q          37077693                                                  40771444    3694                     **AKT2**                                            106
  T11                          19q          37440672                                                  40095021    2654                     **AKT2**                                            57
  T4                           19q          37533808                                                  39695155    2161                     ---                                                 53
  T3                           19q          37553808                                                  39307259    1753                     ---                                                 40
  T4                           19q          44423396                                                  44803072    379                      ---                                                 15
  T11                          19q          43884667                                                  46295324    2411                     ---                                                 89
  T11                          19q          58419791                                                  59082951    663                      ---                                                 33
  T11                          21q          20872889                                                  23530026    2657                     ---                                                 2
  T21                          21q          29671040                                                  31528208    1857                     ---                                                 12
  T45                          21q          32496947                                                  37246707    4749                     ---                                                 16
  T45                          21q          37818180                                                  39354904    1536                     **DYRK1A, KCNJ6**                                   7
  T11                          21q          38668355                                                  39992546    1324                     **DYRK1A, KCNJ6**                                   5
  T11                          22q          16915658                                                  17768070    852                      ---                                                 11
  T2                           Xq           107275387                                                 108021257   745                      ---                                                 2
  T40                          Xq           148845624                                                 149029121   183                      ---                                                 5

Human GRCh37/hg19.

Recurrent altered genes in bold characters.
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![*TGFBR2* homozygous deletions](CAM4-7-3213-g002){#cam41533-fig-0002}

3.4. Genomic gain and focal amplification {#cam41533-sec-0015}
-----------------------------------------

The most significantly frequent minimal regions of gain with a frequency greater than 25% were located at loci 1p36.33 (37%), 1q21.1 (29%), 3q26.32 (57%), 5p15.33 (29%), 8q24.3 (39%), 9q34.3 (33%), 16p13.3 (41%), and 19p13.3 (27%) (Table [1](#cam41533-tbl-0001){ref-type="table"}B; Figure [1](#cam41533-fig-0001){ref-type="fig"}A). The most common frequent minimal region of gain in 57% of ASCCs encompassed the 3q26.32 region containing *PIK3CA* and *TERC* (Figure [S3](#cam41533-sup-0003){ref-type="supplementary-material"}). *PIK3CA (*but not *TERC)* mRNA was significantly overexpressed in the ASCCs with 3q26.32 gains, compared to diploid tumors (*P *=* *.013; Figure [S3](#cam41533-sup-0003){ref-type="supplementary-material"}), suggesting that *PIK3CA* is the likely target of this gain event in this chromosomal region. Other common regions of genomic gain containing known oncogenes were located at 9q34.3 (*NOTCH1*) and 19p13.3 (*FGFR2*) (Table [1](#cam41533-tbl-0001){ref-type="table"}B). Sixty‐three focal amplifications were identified, including 8 recurrent focal amplifications for the loci: *DDR2* (1q23.3; n = 3), *SFRP1* and *NKX6‐3* (8p11.21; n = 2), *MYC* (8q24.21; n = 2), *CCND1* (11q13; n = 3), *MAPRE2* (18q12.1; n = 2), *NFIX, LYL1* (19p13.2; n = 2), *AKT2* (19q13.2; n = 2), and *DYRK1A* and *KCNJ6* (21q22.13; n = 2). It is noteworthy that 7 of the amplified genes in focal amplifications (ie, *DDR2, CDK6, MET, IGF2, MDM2, FLT3,* and *AKT2*) are targets for specific therapies (Table [2](#cam41533-tbl-0002){ref-type="table"}B).

3.5. Comparative genomic analysis of treatment‐naive and recurrent tumor samples {#cam41533-sec-0016}
--------------------------------------------------------------------------------

As described in the literature, accumulation of gains/amplification and/or loss in the genome can generate a pattern of chromosomal alterations, which could specifically contribute to cancer progression. Based on these elements, we investigated whether such patterns of chromosomal abnormalities could be preferentially observed in the 22 recurrent tumors compared to the 27 treatment‐naive tumors. The global load of genomic alterations was similar between relapsed and treatment‐naive tumors, including the number of distinct CGH segments identified \[median = 150 (range: 68‐550) and median = 126 (range: 95‐386), respectively\] and the fraction of altered genome \[median = 15.84 (range: 1.81‐51.94) and median = 18.74 (range: 0.96‐38.03), respectively\] (Table [S4](#cam41533-sup-0007){ref-type="supplementary-material"}). Several individual genomic alterations (Figure [1](#cam41533-fig-0001){ref-type="fig"}B,C) were more frequently (but not statistically significantly) observed in the recurrent tumor group compared to the treatment‐naive tumor group including, for example, heterozygous deletions at 2q35 (36% vs 19%) or gains at 5p15.33 (36% vs 22%) (Table [1](#cam41533-tbl-0001){ref-type="table"}A,B). More surprisingly, several individual genomic alterations were statistically more frequently observed in the treatment‐naive tumor group as compared to the recurrence tumor group, in particular heterozygous deletions at 11q14.2 (48% vs 9%; *P *=* *.003) or gains at 19q13.42 (33% vs 5%; *P *=* *.03) (Table [1](#cam41533-tbl-0001){ref-type="table"}A,[1](#cam41533-tbl-0001){ref-type="table"}B). It is noteworthy that the 11q14.2 deleted region contains the well‐known tumor suppressor gene *EED* that also shows a homozygous deletion (Table [2](#cam41533-tbl-0002){ref-type="table"}A).

3.6. Mutations and CNA involved in key cell signaling pathways in ASCC {#cam41533-sec-0017}
----------------------------------------------------------------------

Data concerning *PIK3CA, KRAS,* and *TP53* mutations and the most frequent CNA were combined to characterize genomic alterations in the main signaling pathways altered in human cancers. Nineteen of the 49 tumors (38.8%) harbored gene mutations: *PIK3CA* mutation in 16 (32.6%) cases, *KRAS* mutation in 2 (4.1%) cases, and *TP53* mutation in 2 (4.1%) cases. One tumor harbored both a *KRAS* mutation and a *TP53* mutation. All tumors were wild‐type for *BRAF* gene. The distribution of molecular, biological, pathological, and clinical parameters was similar between treatment‐naive tumors and recurrences, except for *PIK3CA (*or *KRAS)* mutations, which were significantly more frequent in recurrences (*P *=* *.02) (Table [S3](#cam41533-sup-0006){ref-type="supplementary-material"}).

Among CNAs, only focal amplifications and homozygous deletions were integrated in signaling pathways (Table [3](#cam41533-tbl-0003){ref-type="table"}). The most frequently altered pathway in the 49 tumors was the PI3K/Akt/mTOR pathway, which was altered in 22 of the 49 tumors (44.9%). PI3K/Akt/mTOR pathway alterations included activating mutations of *PIK3CA*, homozygous deletion of *PTEN,* and focal amplifications of *IGF2* and *AKT2,* and all of these somatic events were mutually exclusive. Interestingly, the PI3K/Akt/mTOR pathway was altered significantly more frequently in recurrences than in treatment‐naive tumors (64% vs 30%; *P *=* *.017) (Table [3](#cam41533-tbl-0003){ref-type="table"}). It is noteworthy that the RAS/MAPK signaling pathway was rarely altered (2 of the 49 tumors; 4.1%).
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3.7. Correlation between genomic indices and clinicopathological features and prognostic value {#cam41533-sec-0018}
----------------------------------------------------------------------------------------------

As this retrospective cohort of 49 ASCC patients comprised tumor samples with heterogeneous sites and treatment status, the study population was divided into 2 groups of patients (treatment‐naive tumors and recurrences) to study the association between the 2 genomic indices (number of distinct CGH segments identified and fraction of genome altered) and the patients' clinicopathological characteristics, and the impact of these 2 indices on OS.

The first group of treatment‐naive tumors from 27 ASCC patients treated by first‐line exclusive RT/CRT (Table [S3](#cam41533-sup-0006){ref-type="supplementary-material"}) had a median follow‐up of 44.6 months (range: 13.9‐169 months). The overall recurrence rate was 29.6% (n = 8 of 27). No correlation was observed between the 2 genomic indices and OS (data not shown).

The second group of 22 recurrent tumor samples (20 anal recurrences treated by APR and 2 metastases) from patients with ASCC who experienced recurrence after first‐line RT or CRT (Table [S3](#cam41533-sup-0006){ref-type="supplementary-material"}) had a median follow‐up of 46.7 months (range: 9.8‐278 months). The overall mortality rate after recurrence was 63.4% (n = 14 of 22).

Long‐rank test demonstrated a significant correlation between poor OS and a large number of distinct CGH segments in recurrent tumors (*P *=* *.024) (Figure [3](#cam41533-fig-0003){ref-type="fig"}A), and a trend toward significance for a high fraction of the genome altered in treatment‐naive tumors (*P *=* *.16) (Figure [3](#cam41533-fig-0003){ref-type="fig"}B). No correlation was observed between the number of distinct CGH segments and clinicopathological characteristics in the group of 22 recurrent tumors (Table [S5](#cam41533-sup-0008){ref-type="supplementary-material"}) or in the group of 29 treatment‐naive tumors (data not shown).

![Overall survival in the 22 ASCC patients with recurrent tumors depending on the "distinct CGH segments" status (A) and the "fraction of genome altered" status (B)](CAM4-7-3213-g003){#cam41533-fig-0003}

4. DISCUSSION {#cam41533-sec-0019}
=============

ASCC is considered to be a highly radiosensitive tumor, but 20% of patients fail to respond to CRT. No predictive markers of response to radiation‐based therapy have been prospectively validated. Moreover, in patients who develop recurrence, APR is the treatment of choice, but no prognostic factors have been identified and no adjuvant therapy has been recommended. More accurate genomic characterization of anal carcinogenesis is crucial to improve the medical care of patients with ASCC by identifying new therapeutic targets or prognostic biomarkers. In this context, we conducted a large array comparative genomic hybridization analysis in treatment‐naive and recurrent ASCC.

Despite previous exposure to ionizing radiation and DNA‐damaging cytotoxic chemotherapy, the global load of genomic alterations was high but similar between treatment‐naive tumors and recurrences, in line with the mutational burden described in whole‐exome analysis of ASCC[17](#cam41533-bib-0017){ref-type="ref"} and in other types of carcinoma.[18](#cam41533-bib-0018){ref-type="ref"}, [19](#cam41533-bib-0019){ref-type="ref"} Surprisingly, several individual genomic alterations were observed more frequently in the group of treatment‐naive tumors.

A significant correlation was demonstrated between genomic index and OS in the group of recurrent tumors (not observed in the group of treatment‐naive tumors), with a high number of distinct CGH segments associated with poor prognosis. Due to the little size of our cohort, this correlation needs to be confirmed in a larger prospective randomized study.

Several recurrent minimal heterozygous deleted regions were identified in this study. It is noted that our methodology (CGH microarray but not SNP array) did not allow to estimate copy number neutral loss of heterozygosity (LOH). The most common frequent minimal region of deletion encompassed the 11q22.3 region, containing *ATM*. Five recurrent homozygous deletions were identified in the *TGFBR2* (8%), *MACROD2* (6%), *PTEN* (4%), *LRP1B* (4%), and *TRAF3* (4%) loci. Homozygous deletions of *TGFBR2*,*LRP1B,* and *TRAF3* genes have never been previously reported in ASCC. The *TGFBR2* gene is involved in homeostasis of many tissues via the TGFβ signaling pathway. It encodes a tyrosine kinase receptor that is involved in cell proliferation, epithelial‐mesenchymal transition, and apoptosis. Bi‐allelic inactivation of TGFBR2 using a keratin 14 promoter in mice leads to spontaneous genital and anal SCC.[20](#cam41533-bib-0020){ref-type="ref"} Homozygous deletion of *TGFBR2* has been reported in gastric and pancreatic cancer,[21](#cam41533-bib-0021){ref-type="ref"}, [22](#cam41533-bib-0022){ref-type="ref"} and alteration of *TGFBR2* expression is associated with poor prognosis in several cancers.[23](#cam41533-bib-0023){ref-type="ref"}, [24](#cam41533-bib-0024){ref-type="ref"} The *LRP1B* gene encodes a member of the LDL receptor family of lipoprotein receptors that is involved in cholesterol metabolism and atherosclerotic lesion formation. Homozygous deletion of *LRP1B* has been reported in multiple malignancies, namely esophageal cancer, glioblastoma, and cervical cancer.[25](#cam41533-bib-0025){ref-type="ref"}, [26](#cam41533-bib-0026){ref-type="ref"}, [27](#cam41533-bib-0027){ref-type="ref"} *LRP1B* gene has been recently identified as the integration site for HPV in cervical and oropharyngeal cancers.[27](#cam41533-bib-0027){ref-type="ref"}, [28](#cam41533-bib-0028){ref-type="ref"} The *TRAF3* gene encodes a cytoplasmic adaptor protein, with E3 ligase activity, which is involved in the signaling of a variety of adaptive and innate immune receptors as well as cytokine receptors. In particular, homozygous deletions of the *TRAF3* gene have been detected in hematopoietic malignancies, such as multiple myeloma, non‐Hodgkin lymphoma, and B‐cell chronic lymphocytic leukemia.[29](#cam41533-bib-0029){ref-type="ref"}, [30](#cam41533-bib-0030){ref-type="ref"} *TRAF3* has recently been shown to be downregulated by HPV via upregulation of *UCHL1* with suppression of the innate immune response in keratinocytes.[31](#cam41533-bib-0031){ref-type="ref"}

Several recurrent minimal regions of gain were identified. The most common frequent minimal region of gain, observed in 66% of ASCCs, encompassed the 3q26.32 region containing *PIK3CA* and *TERC*. Moreover, the RNA results identified *PIK3CA* (and not *TERC*) as the driver gene of this 3q26.32 region of gain. The PI3K/Akt/mTOR pathway has been often identified in previous ASCC sequencing studies with PIK3CA mutations in 20% to 30% of ASCC.[32](#cam41533-bib-0032){ref-type="ref"}, [33](#cam41533-bib-0033){ref-type="ref"} Other common regions of genomic gain that contain known oncogenes, with potential therapeutic interest, were located at 9q34.3 (*NOTCH1*) and 19p13.3 (*FGFR2*).

Several recurrent focal amplifications of known oncogenes with possible therapeutic implications were also identified: *AKT2* (8%)*, DDR2* (6%), and *IGF2* (4%), which are known to be targets for specific therapies and which could be used as novel agents in the treatment of ASCC. The *AKT2* gene is a partner of the PI3K/Akt/mTOR pathway and is known to be amplified in HPV‐associated squamous cell cancers.[34](#cam41533-bib-0034){ref-type="ref"} Four of the other focal amplifications (ie, *CDK6, MET, MDM2, and FLT3*) are also targets for specific therapies.

Considering the high prevalence of HPV infection in ASCC (approximately 95%) and its well‐established role in the first steps of anal carcinogenesis, it seems difficult to distinguish signaling pathway changes caused by genetic mutations from those caused by HPV. However, *TP53* mutations have been reported more frequently in the rare HPV‐negative cases of ASCC[10](#cam41533-bib-0010){ref-type="ref"}, [33](#cam41533-bib-0033){ref-type="ref"}, [35](#cam41533-bib-0035){ref-type="ref"}, [36](#cam41533-bib-0036){ref-type="ref"} and could therefore be involved in another pathway of anal carcinogenesis.

In conclusion, this study represents the largest array comparative genomic hybridization analysis in treatment‐naive and recurrent ASCC. The results of this study further our knowledge of the genetic landscape of ASCC and highlight the crucial role of biological and molecular characterization of rare diseases for the development of new treatments. This study identifies new tumor suppressor genes, *LRP1B* and *TRAF3*, with possible interactions with HPV and confirmed the role of *TGFBR2* and *PTEN* in ASCC carcinogenesis. We confirm the major role of activation of the PI3K/Akt/mTOR pathway in ASCC carcinogenesis (45% of tumors samples) as previously described,[32](#cam41533-bib-0032){ref-type="ref"}, [33](#cam41533-bib-0033){ref-type="ref"} and in particular in recurrences, in which activation of this pathway was present in 66% of tumor samples. We also suggest several druggable target genes of this signaling pathway, such as *IGF2*,*PIK3CA,* and *AKT2*.

Clinical studies based on prospective cohorts of patients with ASCC need to be conducted in order to demonstrate the antitumor efficacy of new targeting agents in light of the molecular alterations identified in the present study.
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